CLSD - クリアサイド・バイオメディカル (Clearside Biomedical Inc.) クリアサイド・バイオメディカル

 CLSDのチャート


 CLSDの企業情報

symbol CLSD
会社名 Clearside Biomedical Inc (クリアサイド・バイオメディカル)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 クリアサイド・バイオメディカル(Clearside Biomedical Inc.)は目のまばゆい病気を治療するための業界初の薬物療法を開発している臨床生物医薬品会社である。同社の製品候補は、網膜に影響を及ぼす病気に重点を置く。網膜は、目の内部を覆う組織であり、主に視力の原因である。網膜に隣接する層である脈絡膜は、網膜に血液、酸素、栄養を供給する。そのマイクロインジェクターでは、脈絡膜と強膜と呼ばれる眼の外側保護層との間に位置する脈絡膜上腔(SCS)内に薬物が注入されて広がる。脈絡膜上皮の注射では、眼の中心部を占めるゼリー様物質である硝子体への薬物の注射など、他の眼内薬物投与技術と比較して、その脈絡膜の生成物候補が網膜および脈絡膜に直接的に投与される。   クリアサイド・バイオメディカルは米国のバイオ医薬品企業。後期臨床段階で、主に眼科疾患のための薬物送達技術の開発に焦点を当てる。同社の登録商標製品である「SCSマイクロインジェクタ―」は網膜と、黄斑浮腫を伴う病気に関連する脈絡膜を治療するために使用される。本社はジョ―ジア州アルファレッタ。   Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside's proprietary SCS Microinjector® targets the suprachoroidal space (SCS®) and offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company's SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications.
本社所在地 900 North Point Parkway Suite 200 Alpharetta GA 30005 USA
代表者氏名 Christy L. Shaffer Christy L. Shaffer
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 678-270-3631
設立年月日 40664
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数
url www.clearsidebio.com
nasdaq_url https://www.nasdaq.com/symbol/clsd
adr_tso
EBITDA EBITDA(百万ドル) -71.68200
終値(lastsale) 5.8001
時価総額(marketcap) 185743695.8223
時価総額 時価総額(百万ドル) 185.10000
売上高 売上高(百万ドル) 0.21000
企業価値(EV) 企業価値(EV)(百万ドル) 110.51800
当期純利益 当期純利益(百万ドル) -72.13700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Clearside Biomedical Inc revenues decreased from $135K to $0K. Net loss increased 55% to $37.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 62% to $29.8M (expense) General and administrative increase of 27% to $5.2M (expense).

 CLSDのテクニカル分析


 CLSDのニュース

   Clearside Biomedical Inc. (NASDAQ:CLSD) Stock Ripped -21.09% Year-To-Date, What Will Happen Next?  2022/04/09 18:00:00 Marketing Sentinel
In last trading session, Clearside Biomedical Inc. (NASDAQ:CLSD) saw 0.36 million shares changing hands with its beta currently measuring 2.09. Company’s recent per share price level of $2.17 trading at -$0.2 or -8.44% at ring of the bell on the day assigns it a market valuation of $127.70M. That closing price of CLSD’s stock is … Clearside Biomedical Inc. (NASDAQ:CLSD) Stock Ripped -21.09% Year-To-Date, What Will Happen Next? Read More »
   Clearside Biomedical to Present at the Needham Virtual Healthcare Conference  2022/04/06 11:05:00 GlobeNewswire
ALPHARETTA, Ga., April 06, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will present at the Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 3:45 p.m. ET.
   Thinking about buying stock in ORIC Pharmaceuticals, WiMi Hologram Cloud, Clearside Biomedical, Stronghold Digital Mining, or GasLog Partners?  2022/03/28 13:31:00 Benzinga
NEW YORK , March 28, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ORIC, WIMI, CLSD, SDIG, and GLOP. … Full story available on Benzinga.com
   Bausch Health, Clearside launch vision disorder therapy Xipere in US  2022/03/28 12:15:52 Seeking Alpha
Bausch Health (BHC) and Clearside Biomedical (CLSD) launched eye disorder therapy Xipere (triamcinolone acetonide injectable suspension) in the U.S.The companies said Xipere is the…
   Clearside Biomedical Inc. (NASDAQ: CLSD) Is One Of The Hottest Stocks Right Now.  2022/03/22 15:30:00 Stocks Register
Clearside Biomedical Inc. (NASDAQ:CLSD) price closed lower on Monday, March 21, dropping -10.31% below its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << A look at the daily price movement shows that the last close reads $2.62, with intraday deals fluctuated between $2.33 and $2.7124. … Clearside Biomedical Inc. (NASDAQ: CLSD) Is One Of The Hottest Stocks Right Now. Read More »
   FY2021 Earnings Forecast for Clearside Biomedical, Inc. Issued By Wedbush (NASDAQ:CLSD)  2021/12/24 11:26:42 Dakota Financial News
Clearside Biomedical, Inc. (NASDAQ:CLSD) – Stock analysts at Wedbush reduced their FY2021 EPS estimates for Clearside Biomedical in a research note issued to investors on Tuesday, December 21st. Wedbush analyst A. Argyrides now anticipates that the company will post earnings of ($0.43) per share for the year, down from their prior estimate of ($0.42). Wedbush […]
   HC Wainwright Reaffirms Buy Rating for Clearside Biomedical (NASDAQ:CLSD)  2021/12/23 08:46:41 Dakota Financial News
HC Wainwright reissued their buy rating on shares of Clearside Biomedical (NASDAQ:CLSD) in a research report report published on Wednesday, Price Targets.com reports. The firm currently has a $10.00 price target on the stock. CLSD has been the subject of several other reports. JMP Securities restated a buy rating and set a $11.00 target price []
   Diabetic Macular Edema Market Size, Landscape, Industry Analysis, Business Outlook, Current and Future Growth By 2028 | Pfizer Inc, Allergan PLC, Novartis AG, Clearside Biomedical Inc, Ariam Pharmaceuticals, Valeant Pharmaceuticals, Regenron PLC, Bayer AG  2021/12/14 11:13:00 OpenPR
New Jersey, United States,- Verified Market Research has recently published a research report titled, Diabetic Macular Edema Market Size, and Forecast 2021-2028, Breakdown Data by Manufacturers, Key Regions, Types and Application. Primary and secondary research methodologies have been used to
   Clearside Biomedical to join Nasdaq Biotechnology Index  2021/12/13 23:00:01 Seeking Alpha
   Clearside Biomedical Added to the Nasdaq Biotechnology Index  2021/12/13 21:05:00 Intrado Digital Media
ALPHARETTA, Ga., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that the Company will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021.
   State Street Corp Increases Position in Clearside Biomedical, Inc. (NASDAQ:CLSD)  2021/12/05 09:08:41 Dakota Financial News
State Street Corp raised its position in Clearside Biomedical, Inc. (NASDAQ:CLSD) by 316.7% during the second quarter, HoldingsChannel reports. The firm owned 165,588 shares of the companys stock after buying an additional 125,848 shares during the quarter. State Street Corps holdings in Clearside Biomedical were worth $806,000 as of its most recent SEC filing. Several []
   Short Interest in Clearside Biomedical, Inc. (NASDAQ:CLSD) Drops By 52.3%  2021/11/30 19:54:43 Transcript Daily
Clearside Biomedical, Inc. (NASDAQ:CLSD) was the target of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 1,050,000 shares, a drop of 52.3% from the October 31st total of 2,200,000 shares. Based on an average trading volume of 512,500 shares, the short-interest ratio is []
   Short Interest in Clearside Biomedical, Inc. (NASDAQ:CLSD) Decreases By 52.3%  2021/11/29 07:12:41 Dakota Financial News
Clearside Biomedical, Inc. (NASDAQ:CLSD) was the target of a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 1,050,000 shares, a decline of 52.3% from the October 31st total of 2,200,000 shares. Approximately 2.2% of the companys shares are sold short. Based on an average []
   Clearside Biomedical, Inc. (NASDAQ:CLSD) Expected to Post Quarterly Sales of $13.73 Million  2021/11/21 17:50:43 Transcript Daily
Equities research analysts predict that Clearside Biomedical, Inc. (NASDAQ:CLSD) will report sales of $13.73 million for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Clearside Biomedicals earnings. The lowest sales estimate is $3.07 million and the highest is $24.00 million. Clearside Biomedical posted sales of $10,000.00 during the same []
   Clearside Biomedical, Inc. (NASDAQ:CLSD) Short Interest Update  2021/11/19 18:20:42 Dakota Financial News
Clearside Biomedical, Inc. (NASDAQ:CLSD) saw a large growth in short interest in the month of October. As of October 29th, there was short interest totalling 2,200,000 shares, a growth of 81.8% from the October 14th total of 1,210,000 shares. Based on an average trading volume of 553,200 shares, the days-to-cover ratio is currently 4.0 days. […]

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 クリアサイド・バイオメディカル CLSD Clearside Biomedical Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)